A UCLA-led team has described how it advanced an experimental CRISPR approach for sickle cell disease into a blood stem cell therapy that can be manufactured at the scale and quality required for a clinical trial.
❓ Unknown
UCLA Team Advances CRISPR Therapy for Sickle Cell Disease to Clinical Trial Stage
Just now
November 5, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
A UCLA-led team has successfully advanced a CRISPR-based therapy for sickle cell disease into a clinically viable blood stem cell treatment. This development is significant as it showcases advancements in gene editing technology that could have implications for healthcare in Iran. The ability to manufacture such therapies at scale could enhance medical innovation in the region.
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Davoud Rokhbin Executed for Murder in Kashan Prison
Just now •
Ali Mokhtari Executed for Rape in Shahre Kord
14 min ago •
Ultrashort Laser Pulses Enhance Control of Quantum Materials
15 min ago •
Iran's War and Rising Living Costs: Factors Behind Republican Defeat in U.S. Elections
18 min ago •